Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15645408 | 1.00 | LTA4H (0.44) | LTA4HGPR119LIPEMEN1KMT2A | |
| SCHEMBL8235660 | 0.89 | LTA4H (0.47) | LTA4HGPR119LIPE | |
| SCHEMBL13705093 | 0.89 | SCN9A (0.38) | GPR119CHEK2 | |
| SCHEMBL8239012 | 0.89 | GPR119 (0.53) | GPR119MEN1KMT2ACHEK2 | |
| SCHEMBL13705091 | 0.89 | LTA4H (0.46) | LTA4HGPR119ADRB1 | |
| SCHEMBL15645152 | 0.89 | LTA4H (0.46) | LTA4HGPR119ADRB1 | |
| SCHEMBL3493648 | 0.89 | LTA4H (0.46) | LTA4HGPR119ADRB1 | |
| SCHEMBL3492651 | 0.87 | CHEK2 (0.44) | GPR119CHEK2HDAC1ADRB1 | |
| SCHEMBL8238791 | 0.86 | GPR119 (0.40) | GPR119CHEK2ADRB1 | |
| SCHEMBL15645473 | 0.85 | HPGD (0.42) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | LTA4H 4622/4885GPR119 1597/4885LIPE 4395/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | LTA4H 4659/4885GPR119 1686/4885LIPE 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.